Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma-Reference-Cited by-同舟云学术

Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma

Published:2009-03 Issue:6 Volume:144 Page:887-894
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Popat Rakesh,Oakervee Heather,Williams Catherine,Cook Mark,Craddock Charles,Basu Supratik,Singer Charles,Harding Stephen,Foot Nicola,Hallam Simon,Odeh Liz,Joel Simon,Cavenagh Jamie

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2008.07572.x/fullpdf

Reference26 articles.

1. A strategic framework for novel drug development in multiple myeloma;Anderson;British Journal of Haematology,2007

2. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up;Berenson;Annals of Hematology,2008

3. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant;Blade;British Journal of Haematology,1998

4. International uniform response criteria for multiple myeloma;Durie;Leukemia,2006

5. Use of free light chain measurements as prediction of response to induction chemotherapy;Harding;British Journal of Haematology,2007

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN ‐003/ MYX .1 single arm phase II trial;American Journal of Hematology;2021-04-12

2. DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment;Cancers;2021-01-28

3. Natural History of Chemotherapy-Induced Peripheral Neuropathy;Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced Neuropathy;2021

4. Bortezomib and other proteosome inhibitors—induced peripheral neurotoxicity: From pathogenesis to treatment;Journal of the Peripheral Nervous System;2019-10

Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis

;Drug Design, Development and Therapy;2019-05